Abstract:Background: ApoA5, the newest member of the apolipoprotein family, is expressed exclusively in the liver.Although plasma ApoA5 concentrations in humans are very low (114-258 ng/mL) and ~1,000-fold lower than those of ApoB100 on a molar basis, human and mouse studies have clearly shown a key role of ApoA5 in plasma triglyceride (TG) homeostasis.Because ~20% of ApoA5 is secreted into the circulation and its concentration is 7-fold higher in the liver than in plasma, we hypothesize that ApoA5 plays a critical role in regulating hepatic TG metabolism and ApoA5 deficiency profoundly perturbs the balance of daily input and output of fatty acids (FA) in the liver.Methods: Male ApoA5 KO and WT mice were fed a chow diet for 12 mo.Liver pathology was examined by H&E and Sirius Red staining.Lipid droplets (LD) and endoplasmic reticulum (ER) and Golgi fractions were isolated from homogenized liver by ultracentrifugation.Gene expression and protein content were studied by qRT-PCR and Western blots.Lipidomic analysis of liver was performed by ESI-MS/MS.Results: During the 12-mo period, on chow, ApoA5 deficiency significantly reduced TG disposal by inhibiting FA β-oxidation through repressing carnitine palmitoyltransferase-1, coupled with reduced energy expenditure.In WT mice, because it is a LD-associated protein, ApoA5 guided TG-rich LD to the ER for VLDL assembly and subsequently to the Golgi apparatus for hepatic VLDL secretion through its interaction with Plin2, Cideb and ApoB100.ApoA5 deficiency reduces hepatic VLDL secretion by impairing its lipidation and maturation.As a result, accumulation of excess TG within the cytoplasm of hepatocytes induced the formation of numerous large LD, leading to liver steatosis.ApoA5 deficiency significantly increased de novo synthesis of ceramides, the major FA metabolites, by enhancing hepatic serine palmitoyltransferase activity.Due to their hepatocellular lipotoxicity, increased ceramides induced hepatic lipoapoptosis through TNFα by stimulating both caspase-induced apoptosis and ROS-mediated mitochondrial dysfunction in ApoA5 KO, but not WT mice.These alterations triggered NASH with a main histological feature of hepatocellular ballooning in ApoA5 KO mice.Ceramide-induced hepatocyte apoptosis and activation of hepatic stellate cells promoted fibrogenesis by triggering a profibrogenic gene program, leading to liver fibrosis.Conclusions: ApoA5 deficiency in chow-fed mice over a long period leads to spontaneous development of NAFLD, gradually evolving from simple steatosis to NASH, and subsequently to liver fibrosis, which closely recapitulates many aspects of the pathogenic process of NAFLD in patients.These innovative studies will help us understand the mechanisms underlying the critical role of ApoA5 in the pathogenesis of NAFLD and provide novel targets to combat NAFLD by pharmacological intervention.

New Insights into Apolipoprotein A5 in Controlling Lipoprotein Metabolism in Obesity and the Metabolic Syndrome Patients

The role of apolipoprotein A5 in obesity and the metabolic syndrome.

Apolipoprotein A5 regulates intracellular triglyceride metabolism in adipocytes

New Insights into Apolipoprotein A5 and the Modulation of Human Adipose-derived Mesenchymal Stem Cells Adipogenesis.

Decreased Apolipoprotein A5 is Implicated in Insulin Resistance-Related Hypertriglyceridemia in Obesity.

Apolipoprotein A5 internalized by human adipocytes modulates cellular triglyceride content.

Apolipoprotein A1 Inhibits Adipogenesis Progression of Human Adipose-Derived Mesenchymal Stem Cells

The Exchangeable Apolipoproteins in Lipid Metabolism and Obesity

Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease

[A Novel Gene in APOA1/C3/A4/A5 Cluster: Apolipoprotein A5].

41 Cholesterol 7Α-Hydroxylase (CYP7A1) Mediates Resistance to High-Fat Diet-Induced Obesity and Diabetes Through Elevated Tauro-β-Muricholic Acid and Inhibition of Farnesoid X Receptor Signaling in the Intestine

Apolipoprotein A5 Inhibits Adipogenesis of AMSCs Potentially Through the Cidec Pathway

Effects and mechanisms of apolipoprotein A-V on the regulation of lipid accumulation in cardiomyocytes

[The Role of Apolipoprotein C3 in the Regulation of Nonalcoholic Fatty Liver Disease, Glucose and Lipid Metabolism, and Islet Β Cell Function].

Intracellular role of exchangeable apolipoproteins in energy homeostasis, obesity and non-alcoholic fatty liver disease.

A Role of Apolipoprotein D in Triglyceride Metabolism.

Intracellular Role of Exchangeable Apolipoproteins in Energy Homeostasis, Obesity and Non‐alcoholic Fatty Liver Disease

Insights into the roles of Apolipoprotein E in adipocyte biology and obesity

Apolipoprotein E Synthesized by Adipocyte and Apolipoprotein E Carried on Lipoproteins Modulate Adipocyte Triglyceride Content

Regulation of adipocyte autophagy — The potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-I

1822-P: Regulation of Trafficking of Lipids from Liver to Fat by ApoA4 in a Mouse Model of Nonalcoholic Steatohepatitis